Please assess the completion status of the following clinical trial:

Trial Title: Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Informed consent obtained~* Body Mass Index (BMI) of 30.0 kg/m\^2 or above~* Body Mass Index (BMI) of 27 kg/m\^2 or above in the presence of co-morbidities of treated or untreated dyslipidemia and/or hypertension~* Stable body weight~* Preceding failed dietary effort~Exclusion Criteria:~* Known type 1 or type 2 diabetes~* Glycosylated haemoglobin (HbA1c) of 6.5 % or above (Screening visit 1) or FPG of 126 mg/dL (7 mmol/L) or above (Screening visit 2) or 2 hour post-challenge (OGTT) plasma glucose of 200 mg/dL (11.1 mmol/L) or above (Screening visit 2)~* Screening calcitonin of 50 ng/L or above~* Family or personal history of multiple endocrine neoplasia type 2 (MEN2) or familial medullary thyroid carcinoma (FMTC)~* Personal history of non-familial medullary thyroid carcinoma~* History of acute or chronic pancreatitis~* Obesity induced by drug treatment~* Use of approved weight lowering pharmacotherapy~* Previous surgical treatment of obesity~* History of major depressive disorder or suicide attempt~* Uncontrolled hypertension (systolic blood pressure of 160 mmHg or above and/or diastolic blood pressure of 100 mmHg or above)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Liraglutide 3.0mg (week0-56)/Liraglutide 3.0mg (week56-68) (Type: EXPERIMENTAL): None
- Liraglutide 3.0mg (week0-56)/Liraglutide Placebo (week56-68) (Type: EXPERIMENTAL): None
- Liraglutide Placebo, no Pre-diabetes (Type: PLACEBO_COMPARATOR): None
- Liraglutide 3.0mg, Pre-diabetes (Type: EXPERIMENTAL): None
- Liraglutide Placebo, Pre-diabetes (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).